Table 3 Independent predictors of 90-day mortality in elderly solid tumor patients (n = 262)

Age (HR for increase of 1 year)

0.98 (0.95–1.01)

0.16

0.99 (0.95–1.03)

0.57

Sex

 Male

1

1

 Female

0.66 (0.46–0.96)

0.03

0.75 (0.43–1.30)

0.30

Performance status

 0–1

1

0.07

1

0.17

 2

1.30 (0.85–1.97)

1.58 (0.97–2.59)

 3–4

1.88 (1.10–3.23)

1.53 (0.77–3.05)

Primary tumor site

 Genitourinary

1

0.005

1

0.01

 Gastrointestinal

1.10 (0.65–1.86)

0.96 (0.49–1.89)

 Breast

0.82 (0.36–1.89)

0.38 (0.11–1.27)

 Lung

1.37 (0.83–2.26)

1.11 (0.59–2.08)

 Head and neck

2.60 (1.49–4.53)

2.69 (1.25–5.79)

 Other

0.75 (0.29–1.96)

0.80 (0.24–2.67)

Metastatic status

 No

1

1

 Yes

0.96 (0.68–1.36)

0.82

1.61 (0.98–2.59)

0.06

Number of previous systemic anti-tumoral treatments

0.88 (0.73–1.07)

0.19

(–)

Reason for ICU admission

 Not related to cancer

1 (–)

0.68

1

0.50

 Related to anticancer drugs

1.07 (0.69–1.67)

0.87 (0.49–1.52)

 Related to cancer progression

1.23 (0.76–2.00)

1.23 (0.66–2.28)

SAPS 2 score (HR for increase of 1 unit)

1.05 (1.04–1.06)

<0.0001

1.05 (1.03–1.06)

<0.0001

Life-support techniques

 Mechanical ventilation use

5.96 (3.91–9.10)

(–)

 Noninvasive ventilation use

0.81 (0.46–1.44)

(–)

 Inotropes use

3.68 (2.54–5.33)

(–)

 Dialysis use

1.28 (0.79–2.08)

(–)

Limitation of active therapies during ICU stay

3.79 (2.59–5.56)

(–)

Laboratory findings (HR for increase of 1 unit)

 Albumin

0.94 (0.89–0.99)

(–)

 Leukocytes

1.01 (1.01–1.02)

0.99 (0.97–1.01)

 Glycemia

1.03 (1.00–1.05)

1.01 (0.98–1.06)

 pH

0.04 (0.01–0.13)

0.85 (0.16–4.41)

 Lactates

1.18 (1.13–1.22)

1.07 (0.99–1.15)

 ASAT

1 (1–1.001)

1 (1–1)